Pfizer announces positive top-line results from two Phase 3 trials of Tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
23 April 2014 | By Pfizer
Pfizer Inc. announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079)...